News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Mar 07, 2017
London, UK, 7 March 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the appoin
Mar 02, 2017
London, UK, 2 Mar 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s C
Feb 08, 2017
London, UK, 8 Feb 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s C
Feb 07, 2017
- Epidiolex® NDA submission and launch preparation on track – - New Positive Phase 2 glioma data further demonstrates value of cannabinoid pipeline -
Feb 07, 2017
- GW intends to advance oncology research and development efforts -
Jan 30, 2017
London, UK,  30 Jan 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 February,
Dec 05, 2016
- Three Positive Phase 3 Epidiolex clinical trials reported in 2016 – - NDA submission and launch preparation on track – -Conference call today at 8:00 a.m. EST-
Dec 05, 2016
- Posters Presented at American Epilepsy Society Annual Meeting - - New data includes key secondary efficacy endpoints -
Dec 01, 2016
- Presentations include clinical results from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet Syndrome, as well as additional independent reports from Epidiolex Expanded Access Program sites -
Nov 30, 2016
London, UK,  30 Nov 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 December,

Pages